Categories: CancerNews

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

– Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT –

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading.

Conference Call and Webcast

Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on May 2, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the company’s website at https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company’s website following the completion of the call.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company’s lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company’s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com

Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com

Media Contact:
Grace Spencer
Taft Communications
609-583-1151
grace@taftcommunications.com 

Staff

Recent Posts

Think Together Expands Executive Team with Matt Scharpnick as Chief of Innovation

Think Together creates new C-suite role to fuel market innovation and transform educational outcomes as…

9 hours ago

MindHYVE.ai™ and Islamabad Diagnostic Centre Forge Strategic Alliance to Launch AGI-Powered Diagnostic Intelligence Across Pakistan

ISLAMABAD, May 22, 2025 /PRNewswire/ -- In a groundbreaking move to elevate clinical diagnostics nationwide,…

9 hours ago

Hexaware Accelerates Delivery Solutions with a New Office in Chicago

CHICAGO, May 22, 2025 /PRNewswire/ -- Hexaware Technologies (NSE: HEXT), a leading global IT services…

15 hours ago

Bulletin from the Annual General Meeting 2025

The Annual General Meeting 2025 of RaySearch Laboratories AB (publ) was held on May 22, 2025,…

15 hours ago

Lofta and Bloom Mental Health Partner to Bridge the Gap Between Sleep Apnea and Mental Health

SAN DIEGO, May 22, 2025 /PRNewswire/ -- Lofta, a leader in at-home sleep apnea testing…

15 hours ago

AMA Establishes CPT Codes for Minimally Invasive ESD Procedure

CENTER VALLEY, Pa., May 22, 2025 /PRNewswire/ -- Olympus Corporation, a global medical technology company…

15 hours ago